Beta/MPZ-Engineered Cell Line for Voltage-Gated Sodium Channel Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying voltage-gated sodium channels are hindered by the interference of endogenous beta subunits in heterologous expression systems, making it difficult to precisely analyze the effects of beta subunits on channel function and develop targeted therapies for associated diseases.
Innovation Solution
A novel cell line, beta/MPZΔ cells, is engineered to lack beta subunit proteins, allowing for the expression of defined voltage-gated sodium channels with specific alpha and beta subunits, enabling high-throughput screening of drug effects on channel gating properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If heterologous cells are used to express voltage-gated sodium channels, then channel function can be studied, but endogenous beta subunits interfere with the analysis of beta subunit effects
Solution Approach 1:
The patent removes endogenous beta subunits from the cell line through gene knockout technology. Specifically, the cell line is engineered to lack SCN1B, SCN2B, SCN3B, and SCN4B genes, which encode beta subunits. This extraction eliminates the harmful interference from endogenous beta subunits while allowing precise study of exogenous beta subunit effects on voltage-gated sodium channels.
Solution Approach 2:
The patent creates a controlled cellular environment by introducing defined exogenous beta subunits (SCN1B, SCN2B, SCN3B, or SCN4B) into the beta-subunit-deficient cell line. These copied beta subunits can be precisely controlled in terms of type, amount, and timing of expression, allowing systematic study of their functional effects without the confounding presence of endogenous beta subunits.
2Measurement precision
If toad oocytes are used to avoid endogenous beta subunits, then beta subunit effects can be studied, but the cells have poor homology in membrane composition and display aberrant pharmacology
Solution Approach 1:
The patent changes the cellular parameters by using human cell lines (HEK293, CHO, or COS-7) instead of toad oocytes. These human cells are genetically engineered to lack endogenous beta subunits while maintaining human-specific membrane composition, lipid content, and pharmacological properties. This parameter change preserves physiological relevance for human disease modeling while enabling precise beta subunit effect analysis.
3Measurement precision
If a clean expression system without beta subunits is created, then specific functions of alpha subunits can be resolved, but such a system does not currently exist in human cells
Solution Approach 1:
The patent performs preliminary gene knockout of beta subunits (SCN1B, SCN2B, SCN3B, SCN4B) and their phylogenetic relatives (MPZ, MPZL1, MPZL2, MPZL3, JAML) before introducing the voltage-gated sodium channel alpha subunits for study. This preliminary action creates a clean cellular background that enables precise resolution of alpha subunit functions without confounding beta subunit interactions.
Data Source
AI summary
In a first aspect, provided herein is a beta/MPZ family-subunit-eliminated (beta/MPZΔ) engineered-cell comprising a cell with functionally inactivated SCN1B, SCN2B, SCN3B, SCN4B, MPZL1, MPZL2, MPZL3, MPZ and JAML genes. In certain aspects, the beta/MPZΔ cell further comprising a defined engineered voltage-gated sodium channel, wherein the engineered voltage-gated sodium channel comprises a sodium channel alpha subunit, at least one sodium channel beta subunit.In certain aspect, provided herein is a method of screening effectiveness of a drug targeting a voltage-gated sodium channel (VGSC) disease or disorder, comprising:(a) culturing a beta/MPZ family-subunit-eliminated (beta/MPZΔ) engineered-cell comprising a cell with functionally inactivated SCN1B, SCN2B, SCN3B, SCN4B, MPZL1, MPZL2, MPZL3, MPZ and JAML genes, and comprising a defined engineered voltage-gated sodium channel, wherein the engineered voltage-gated sodium channel comprises a sodium channel alpha subunit, at least one sodium channel beta subunit;(b) introducing a target drug to the cells;(c) applying a high-throughput patch-clamping to the cells to measure gating properties of the cells in the presence of the drugs as compared to control cells; and(d) comparing the gating properties of the beta/MPZΔ cell the gating properties of the controls cell.